checkAd

     469  0 Kommentare CLJI Worldwide's VIBLOK Addresses Unmet Need in Prevention of Herpes Simplex Virus Transmission in Men and Women

    BAY HARBOR ISLANDS, Florida, July 11, 2017 /PRNewswire/ -- CLJI Worldwide reports strong recruitment for the VIBLOK Safety And perFormancE Trial (SAFE Trial).

    CLJI Worldwide

    Please see here for additional information regarding VIBLOK.

    The CLJI Worldwide SAFE Trial is designed to evaluate the performance of the investigational device, VIBLOK, for adults infected with herpes simplex virus-2 (HSV-2). Over 80% of total study participants are already enrolled in the prospective, comparative multi-center SAFE Trial. Anticipated to last 12 months, the VIBLOK SAFE Trial will likely enroll the required participants ahead of schedule.   

    Dr. Annet Muetstege, Director of Clinical Affairs at Applied Clinical Services and clinical project manager of the VIBLOK SAFE Trial, emphasized that interest in the SAFE Trial has been remarkable. "In all of my years running clinical trials," says Dr. Muetstege, "I have never seen such fast enrollment and continuous in-flow of interested and eligible subjects."

    VIBLOK is a virtually colorless, odorless, and tasteless cream designed to create a protective skin barrier that prevents the passage of viruses (e.g., HSV-2). The SAFE Trial will provide an indication as to whether VIBLOK can safely and effectively block virus passage across the skin in HSV-2 infected people and in doing so, target the currently high prevalence of this sexually transmitted infection (STI) in industrialized and developing countries. If approved, VIBLOK may be used by HSV-2 infected people to prevent spreading the virus, or by non-infected individuals to avoid acquiring the STI.

    "The extraordinary interest in the SAFE Trial is indicative of a true unmet need in the prevention of HSV-2 transmission, which VIBLOK has been developed to address," says Ty Cross, President and Chief Executive Officer of CLJI Worldwide.

    Across the globe, the prevalence of STIs has continued to increase over time, despite efforts to increase awareness, education, and prevention. Genital herpes, caused by HSV-2, is a common, chronic, recurrent, viral STI affecting over 400 million people worldwide. With women more susceptible than men, approximately 19 million people total are newly infected with HSV-2 annually and carry the disease for life (no treatment exists to eradicate the herpes simplex virus from the body). In comparison to other common STIs (e.g., Chlamydia, Gonorrhoeae and Syphilis), the global prevalence of HSV-2 is higher [1].

    Seite 1 von 3


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    CLJI Worldwide's VIBLOK Addresses Unmet Need in Prevention of Herpes Simplex Virus Transmission in Men and Women BAY HARBOR ISLANDS, Florida, July 11, 2017 /PRNewswire/ - CLJI Worldwide reports strong recruitment for the VIBLOK Safety And perFormancE Trial (SAFE Trial). Please see here for additional information regarding VIBLOK. The CLJI Worldwide SAFE Trial …